
Articles
-
1 month ago |
healio.com | Raj Chovatiya |Erin Michael
In this video,Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with psoriasis presented at the 2025 Academy of Dermatology Annual Meeting.
-
1 month ago |
healio.com | Raj Chovatiya |Erin Michael
Healio spoke with Raj Chovatiya, MD, PhD, about results from the phase 3 ICONIC-LEAD trial presented at the 2025 Academy of Dermatology Annual Meeting. The study assessed the use of the interleukin-23 inhibitor icotrokinra (Protagonist Therapeutics, Johnson & Johnson) in adult and adolescent patients with moderate-to-severe plaque psoriasis.
-
2 months ago |
healio.com | Raj Chovatiya |Erin Michael
In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American Academy of Dermatology Annual Meeting. The study assessed the use of ESK-001 (Alumis), an oral tyrosine kinase 2 inhibitor, among patients with moderate-to-severe plaque psoriasis.
-
2 months ago |
healio.com | Raj Chovatiya |Erin Michael |Carol L. DiBerardino
In this video, Raj Chovatiya, MD, PhD, discusses updates on oral therapies in psoriasis from the American Academy of Dermatology Annual Meeting. “We saw updates largely in the oral therapeutic realm, even more so than the biologic therapeutic realm,” Chovatiya, who is a clinical associate professor for Chicago Medical School at Rosalind Franklin University and assistant clinical professor at George Washington University School of Health Sciences, said.
-
Mar 6, 2025 |
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this exclusive video, Lawrence F. Eichenfield, MD, a member of the Healio Dermatology Peer Perspective Board, discusses psoriasis case reports presented at Maui Derm 2025.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →